Cecile Gross
Global Category Manager, Parenteral

Is this your profile?

About

Cécile Gross serves as Global Category Marketing Manager at Nemera, where she leads the strategy, development and lifecycle management of the Parenteral Devices portfolio. Her scope includes advanced delivery platforms such as safety systems, pen injectors and on-body injectors, ensuring they meet evolving market and patient needs. With over 20 years of experience in the medical device industry, she brings deep expertise in marketing of high technology solutions and driving effective product lifecycle strategies across diverse device categories.

Ms Gross holds a degree in International Business and a Master’s in Marketing and Management in the Healthcare Industry from the IMIS Institute in Lyon (France), equipping her with both global business insight and sector-specific leadership capabilities.

Contributions

IMPORTANCE OF BEING PATIENT-CENTRIC IN CARDIOVASCULAR-KIDNEY-METABOLIC CARE

Cécile Gross and Mark Tunkel discuss Nemera's substantial portfolio of user-friendly, effective injectable devices available to meet the needs of patients with diverse chronic conditions.

More contributions

SYMBIOZE^® – THE ELECTROMECHANICAL ON-BODY DRUG DELIVERY SYSTEM FOR LARGE-VOLUME IMMUNOTHERAPIES

Corinne Malica and Cécile Gross discuss the challenges involved in developing a wearable device for on-body drug delivery of advanced biologics, with a focus on the immunotherapy sector, and the technical solutions that can overcome them, using Nemera’s Symbioze^® as an example.

YES, PEN INJECTORS CAN ACCOMMODATE MORE THAN JUST INSULIN

Cécile Gross and Mark Tunkel explore the benefits of pen injectors, highlighting their versatility and ease of use, and introduce Nemera’s novel platforms and how they can be adapted for a wide range of indications, enhancing treatment options and the patient experience.

SYMBIOZE^®: LARGE-VOLUME ON-BODY INJECTOR PLATFORM FOSTERING PATIENTS’ EXPERIENCE

Cécile Gross and Mark Tunkel discuss the how Nemera's on-body injector platform – Symbioze^® – has been developed by drawing on a combination of lessons learned from the history of injection devices and the company’s extensive experience developing drug delivery devices for the parenteral route.

ADDRESSING DIABESITY WITH PEN INJECTOR PLATFORMS

Cécile Gross and Mark Tunkel discuss the variety of pen injector platforms to meet the different needs of diabetes patients.

HOW TO NAVIGATE A COMPLEX CONNECTIVITY ENVIRONMENT

Pascal Dugand, Cécile Gross and Mark Tunkel consider the complexity of the landscape for connected devices and demonstrate how a balance can be achieved between patient needs, technology and the cost of integrating this technology into a device.

CHRONIC PATIENTS AT THE CENTRE OF LARGE-VOLUME SC DELIVERY WITH A SUSTAINABLE ON-BODY INJECTOR

Cécile Gross and Mark Tunkel discuss the role of patient-centricity in the development of Nemera’s sustainable on-body injector platform.

ADDRESSING PEPTIDE THERAPEUTICS WITH A VERSATILE PEN PLATFORM

Cécile Gross and Mark Tunkel discuss the rising demand in peptide therapeutics and how Nemera’s PenVario pen injector platform, coupled with Nemera’s end-to-end service offering, has been designed to help pharma partners achieve success in this sector.

PATIENT JOURNEY AS THE FOUNDATION FOR HOLISTIC CONNECTED DEVICE DEVELOPMENT

Mark Tunkel and Cécile Gross consider the development of connected drug delivery devices and identify how understanding the patient journey from diagnosis to treatment can be used as an early-stage decision-making tool.

#138_2022_Oct_Nemera_Featured

PREFILLED SYRINGES

A HIGH-QUALITY AND ROBUST SAFETY SYSTEM FOR HIGH-VOLUME BIOLOGICS AT HOME

Audrey Chandra and Cécile Gross discuss Nemera’s development of a new product for the safe delivery of high-volume biologics at home.

#137_Sept2022_Nemera_Feature

OFFERING A SMART AND SUSTAINABLE ON-BODY INJECTOR FOR CHRONICALLY ILL PATIENTS

Cécile Gross discusses the unmet drug delivery needs in chronic diseases, and details how Nemera’s answer – the Symbioze^® on-body injector – fulfils these needs.

IMPROVING CLINICAL OUTCOMES WITH A PATIENT-CENTRIC AND REUSABLE PEN PLATFORM

Cécile Gross and Radosław Romańczuk discuss Nemera’s Pendura AD pen platform and present case studies demonstrating how it can be tailored to address the user’s needs and meet pharma industry constraints.

Top